| 32.74 0.26 (0.8%) | 04-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 41.67 |
1-year : | 48.67 |
| Resists | First : | 35.68 |
Second : | 41.67 |
| Pivot price | 32.46  |
|||
| Supports | First : | 31.9 |
Second : | 29.56 |
| MAs | MA(5) : | 32.09 |
MA(20) : | 32.84 |
| MA(100) : | 33.67 |
MA(250) : | 27.37 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 57.5 |
D(3) : | 48.2 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 39.27 | Low : | 13.44 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IDYA ] has closed below upper band by 44.2%. Bollinger Bands are 5.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 33.47 - 33.63 | 33.63 - 33.78 |
| Low: | 31.6 - 31.78 | 31.78 - 31.95 |
| Close: | 32.44 - 32.73 | 32.73 - 32.99 |
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
Fri, 03 Apr 2026
A Look At IDEAYA Biosciences (IDYA) Valuation After New DLL3 Combo Trial Progress And Early Responses - Yahoo Finance
Fri, 03 Apr 2026
IDEAYA Biosciences, Inc. $IDYA Position Decreased by JPMorgan Chase & Co. - MarketBeat
Wed, 01 Apr 2026
A Look At IDEAYA Biosciences (IDYA) Valuation After Early IDE849 And IDE161 Combination Trial Activity - simplywall.st
Tue, 31 Mar 2026
Wedbush Reiterates Outperform Rating for IDEAYA Biosciences (NASDAQ:IDYA) - MarketBeat
Tue, 31 Mar 2026
37,595 Shares in IDEAYA Biosciences, Inc. $IDYA Acquired by Tudor Investment Corp ET AL - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 88 (M) |
| Shares Float | 87 (M) |
| Held by Insiders | 2.4 (%) |
| Held by Institutions | 110.7 (%) |
| Shares Short | 9,720 (K) |
| Shares Short P.Month | 10,000 (K) |
| EPS | -1.28 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 11.64 |
| Profit Margin | -52 % |
| Operating Margin | -869.6 % |
| Return on Assets (ttm) | -9 % |
| Return on Equity (ttm) | -11 % |
| Qtrly Rev. Growth | 55.4 % |
| Gross Profit (p.s.) | -1.1 |
| Sales Per Share | 2.49 |
| EBITDA (p.s.) | -1.79 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -71 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -25.58 |
| PEG Ratio | 0 |
| Price to Book value | 2.81 |
| Price to Sales | 13.14 |
| Price to Cash Flow | -40.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|